The effect of azithromycin on sputum inflammatory markers in bronchiectasis. Analysis from the BAT randomized controlled trial
Authors:
Preprint
- 18 January 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Background Long term macrolide treatment has been found beneficial in bronchiectasis (BE) -pathogical bronchial dilatation- possibly due to a combined anti-bacterial and immunomodulatory effect. The exact mechanism of inflammatory response is unknown. Here, we investigated the effect of maintenance macrolide treatment on the inflammatory response in BE. In addition, we assessed the inflammatory profile in BE in relation to disease severity. Methods During the BAT randomized controlled trial (investigating the effect of 1 year of azithromycin (AZM) in 83 BE patients), data on BE severity, lung function and sputum microbiology was collected. For the current study, a wide range of inflammatory markers were analysed in 3- monthly sputum samples in all participants. Results At baseline, marked neutrophilic but also eosinophilic inflammation was present in both groups, which remained stable throughout the study and was not affected by AZM treatment. Significant upregulation of pro-inflammatory markers correlated with FEV1 < 50% (TNFα, ECP, IL-21, IL-1, p = 0.01–0.05), H. influenzae (HI) colonization (MPO, ECP, MIP-1, TNFα, IL-21, Il-8, IL-1, IL-1α, p < 0.001–0.04) and number of exacerbations (MPO, ECP, VEGF, MMP-9, p = 0.003–0.01). Surprisingly, colonization with P. aeruginosa (PA) was found to correlate with an attenuated inflammatory response compared to non-PA colonized. In placebo-treated patients, presence of an infectious exacerbation was reflected by a significant excessive increase in inflammation as compared to a non-significant upregulation in the AZM-treated patients. Conclusion One year of AZM treatment did not result in attenuation of the inflammatory response in BE. Increasing disease severity and the presence of an exacerbation were reflected by upregulation of pro-inflammatory markers.Keywords
All Related Versions
This publication has 35 references indexed in Scilit:
- Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasisMolecular Immunology, 2013
- Pseudomonas aeruginosainduces vascular endothelial growth factor synthesis in airway epitheliumin vitroandin vivoEuropean Respiratory Journal, 2011
- Immunomodulatory Effects of Macrolide Antibiotics – Part 1: Biological MechanismsRespiration, 2010
- Interleukin-8 Production by Human Airway Epithelial Cells in Response to Pseudomonas aeruginosa Clinical Isolates Expressing Type a or Type b FlagellinsClinical and Vaccine Immunology, 2010
- How Pseudomonas aeruginosa adapts to various environments: a metabolomic approachEnvironmental Microbiology, 2010
- Azithromycin induces anti-viral responses in bronchial epithelial cellsEuropean Respiratory Journal, 2010
- Non-cystic fibrosis bronchiectasisClinical Medicine, 2009
- Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis1Journal of Clinical Pharmacy and Therapeutics, 2006
- Standardisation of spirometryEuropean Respiratory Journal, 2005
- A pilot study of low-dose erythromycin in bronchiectasisEuropean Respiratory Journal, 1999